These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 22023023)

  • 1. Characterization of a hypertriglyceridemic transgenic miniature pig model expressing human apolipoprotein CIII.
    Wei J; Ouyang H; Wang Y; Pang D; Cong NX; Wang T; Leng B; Li D; Li X; Wu R; Ding Y; Gao F; Deng Y; Liu B; Li Z; Lai L; Feng H; Liu G; Deng X
    FEBS J; 2012 Jan; 279(1):91-9. PubMed ID: 22023023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E.
    Ebara T; Ramakrishnan R; Steiner G; Shachter NS
    J Clin Invest; 1997 Jun; 99(11):2672-81. PubMed ID: 9169497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypertriglyceridemia and delayed clearance of fat load in transgenic rabbits expressing human apolipoprotein CIII.
    Ding Y; Wang Y; Zhu H; Fan J; Yu L; Liu G; Liu E
    Transgenic Res; 2011 Aug; 20(4):867-75. PubMed ID: 21120692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABCA1 promotes the de novo biogenesis of apolipoprotein CIII-containing HDL particles in vivo and modulates the severity of apolipoprotein CIII-induced hypertriglyceridemia.
    Kypreos KE
    Biochemistry; 2008 Sep; 47(39):10491-502. PubMed ID: 18767813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apolipoprotein CI causes hypertriglyceridemia independent of the very-low-density lipoprotein receptor and apolipoprotein CIII in mice.
    van der Hoogt CC; Berbée JF; Espirito Santo SM; Gerritsen G; Krom YD; van der Zee A; Havekes LM; van Dijk KW; Rensen PC
    Biochim Biophys Acta; 2006 Feb; 1761(2):213-20. PubMed ID: 16478678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of apolipoprotein CIII increases and CETP reverses diet-induced obesity in transgenic mice.
    Salerno AG; Silva TR; Amaral ME; Alberici LC; Bonfleur ML; Patrício PR; Francesconi EP; Grassi-Kassisse DM; Vercesi AE; Boschero AC; Oliveira HC
    Int J Obes (Lond); 2007 Oct; 31(10):1586-95. PubMed ID: 17471296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipoprotein analysis in transgenic mice expressing human apolipoprotein (apo) A-I and apo C III: use of micromethods in analysis of lipoprotein system in mice.
    Ito Y
    Hokkaido Igaku Zasshi; 1994 Mar; 69(2):312-26. PubMed ID: 8157256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway.
    Jong MC; Dahlmans VE; van Gorp PJ; van Dijk KW; Breuer ML; Hofker MH; Havekes LM
    J Clin Invest; 1996 Nov; 98(10):2259-67. PubMed ID: 8941642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles.
    Aalto-Setälä K; Fisher EA; Chen X; Chajek-Shaul T; Hayek T; Zechner R; Walsh A; Ramakrishnan R; Ginsberg HN; Breslow JL
    J Clin Invest; 1992 Nov; 90(5):1889-900. PubMed ID: 1430212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced high density lipoprotein cholesterol in severe hypertriglyceridemic ApoCIII transgenic mice via lowered hepatic ApoAI synthesis.
    Han Y; Qi R; Liu G
    Biochem Biophys Res Commun; 2015 Jul; 462(4):420-5. PubMed ID: 25969427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe hypertriglyceridemia, reduced high density lipoprotein, and neonatal death in lipoprotein lipase knockout mice. Mild hypertriglyceridemia with impaired very low density lipoprotein clearance in heterozygotes.
    Weinstock PH; Bisgaier CL; Aalto-Setälä K; Radner H; Ramakrishnan R; Levak-Frank S; Essenburg AD; Zechner R; Breslow JL
    J Clin Invest; 1995 Dec; 96(6):2555-68. PubMed ID: 8675619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human apoA-I/C-III/A-IV gene cluster transgenic rabbits: effects of a high-cholesterol diet.
    Recalde D; Baroukh N; Viglietta C; Prince S; Verona J; Vergnes L; Pidoux J; Nazeem Nanjee M; Brites F; Ochoa A; Castro G; Zakin MM; Miller NE; Marie Houdebine L
    FEBS Lett; 2004 Aug; 572(1-3):294-8. PubMed ID: 15304365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An apolipoprotein(a) peptide delays chylomicron remnant clearance and increases plasma remnant lipoproteins and atherosclerosis in vivo.
    Devlin CM; Lee SJ; Kuriakose G; Spencer C; Becker L; Grosskopf I; Ko C; Huang LS; Koschinsky ML; Cooper AD; Tabas I
    Arterioscler Thromb Vasc Biol; 2005 Aug; 25(8):1704-10. PubMed ID: 15905467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of apolipoprotein CIII in triglyceride-rich lipoprotein metabolism.
    Fredenrich A
    Diabetes Metab; 1998 Dec; 24(6):490-5. PubMed ID: 9932215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variation at the lipoprotein lipase and apolipoprotein AI-CIII gene loci are associated with fasting lipid and lipoprotein traits in a population sample from Iceland: interaction between genotype, gender, and smoking status.
    Peacock RE; Temple A; Gudnason V; Rosseneu M; Humphries SE
    Genet Epidemiol; 1997; 14(3):265-82. PubMed ID: 9181356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor.
    Ooi EM; Barrett PH; Chan DC; Watts GF
    Clin Sci (Lond); 2008 May; 114(10):611-24. PubMed ID: 18399797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The expression of intact and mutant human apoAI/CIII/AIV/AV gene cluster in transgenic mice.
    Gao J; Wei Y; Huang Y; Liu D; Liu G; Wu M; Wu L; Zhang Q; Zhang Z; Zhang R; Liang C
    J Biol Chem; 2005 Apr; 280(13):12559-66. PubMed ID: 15649902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced cellular uptake of remnant high-density lipoprotein particles: a mechanism for high-density lipoprotein lowering in insulin resistance and hypertriglyceridemia.
    Xiao C; Watanabe T; Zhang Y; Trigatti B; Szeto L; Connelly PW; Marcovina S; Vaisar T; Heinecke JW; Lewis GF
    Circ Res; 2008 Jul; 103(2):159-66. PubMed ID: 18556574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human apolipoprotein A-II determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome.
    Julve J; Escolà-Gil JC; Rotllan N; Fiévet C; Vallez E; de la Torre C; Ribas V; Sloan JH; Blanco-Vaca F
    Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):232-8. PubMed ID: 19910634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case of moderate hypertriglyceridemia with apolipoprotein E phenotype E4/3.
    Kojima S; Homma Y; Sakane H; Kobayashi T; Ozawa H; Okajima Y
    Tokai J Exp Clin Med; 1996 Dec; 21(4-6):165-9. PubMed ID: 9300976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.